Cocrystal Pharma (NASDAQ:COCP) Director Phillip Md Et Al Frost Purchases 20,000 Shares of Stock

Cocrystal Pharma, Inc. (NASDAQ:COCP) Director Phillip Md Et Al Frost acquired 20,000 shares of the company’s stock in a transaction dated Tuesday, November 25th. The shares were bought at an average cost of $0.94 per share, for a total transaction of $18,800.00. Following the completion of the acquisition, the director directly owned 1,699,551 shares of the company’s stock, valued at approximately $1,597,577.94. The trade was a 1.19% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Cocrystal Pharma Price Performance

Shares of COCP stock opened at $0.94 on Wednesday. The firm has a market capitalization of $12.98 million, a price-to-earnings ratio of -1.00 and a beta of 2.24. The business has a fifty day moving average of $1.12 and a 200 day moving average of $1.41. Cocrystal Pharma, Inc. has a 1 year low of $0.90 and a 1 year high of $3.26.

Cocrystal Pharma (NASDAQ:COCP) last posted its quarterly earnings results on Friday, November 14th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.03. As a group, equities research analysts expect that Cocrystal Pharma, Inc. will post -1.85 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cocrystal Pharma in a report on Tuesday, November 18th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $6.00.

About Cocrystal Pharma

Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections.